Pfizer’s Leukemia Drug Receives Green Light from FDA
The U.S. Food and Drug Administration officially approved Pfizer Inc’s (NYSE:$PFE) drug, Mylotarg, for the treatment of myeloid leukemia.
The drug was given the green ligt to treat adults with newly diagnosed AML …
ImmunoGen had an Impressive 12% Climb Today
The latest teaser in the biotechnology sector: Irish biotech company Jazz Pharmaceuticals (NASDAQ:$JAZZ) has signed a deal with ImmunoGen Inc. (NASDAQ:$IMGN) in the development of drugs in the Massachusetts-based company pipelines. This sent shares soaring …
The Market Empties On Otonomy Inc. Stock
Following truly abysmal results from a pivotal Phase 3 trial for its steroid candidate Otividex, Otonomy Inc. (NASDAQ:$OTIC) saw its investors parachuting out of their shares. The number? A cool 81.5% decrease.
While …
New Era of Cancer Treatment: Watch Out for Gilead
On August 30th, the U.S. Food and Drug Administration (FDA) approved Novartis AG (NASDAQ:$NVS)’s leukemia treatment, the first time that a highly anticipated new type of potent gene-modifying immunotherapy has been approved in the United …
Juno Therapeutics Blasting Off Today
Thanks to the $12 billion buyout of its rival, Kite Pharma (NASDAQ:$KITE) by Gilead Sciences (NASDAQ:$GILD) yesterday, Juno Therapeutics (NASDAQ:$JUNO) is having a solid day. Its shares have reached double digits for a second day …
5 Ways the Gilead-Kite Acquisition Might be Profitable
While company acquisitions are sometimes cause for alarm among investors, Gilead Sciences’ (NASDAQ:$GILD) recent buyout of Kite Pharma (NASDAQ:$KITE) at $180 per share may have been a smart move toward long-term growth and profitable outcomes …
Promising Research Spurs Gilead’s $12 Billion Acquisition of Kite
In a $12 billion acquisition announced Monday morning, Gilead Sciences Inc. (NASDAQ:$GILD) has expressed intent in purchasing Kite Pharma Inc (NASDAQ:$KITE), making an attempt to rejuvenate its revenue stream. The move was made to support …
Adamas Pharmaceuticals’ Stock Skyrockets After its Drug Gocovri Gain FDA Approval
Drug manufacturer and research company Adamas Pharmaceuticals (NASDAQ:$ADMS) saw its shares rise on Friday, August 25th. The rise can largely be attributed to the fact that the U.S. Food and Drug Administration (FDA) granted approval …
Johnson & Johnson to Pay $417 Million in Damages After Lawsuit Claims the Company Did Not Properly Address Cancer Risks of its Products
On Monday, August 21st, pharmaceutical giant Johnson & Johnson (NYSE:$JNJ) lost a lawsuit and was ordered to pay a total of $417 million in damages to Eva Echeverria. $70 million was to be paid in …
Mylan NV Just Wrapped Up the $465 Million EpiPen Settlement
The public has now been made aware that Mylan NV (NASDAQ:$MYL) has finalized a $465 million deal with the United States Department of Justice. This is significant news as it marks the end of a …